董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Gerald Chan | 男 | Chairman of the Board of Directors | 66 | 未披露 | 未持股 | 2017-11-09 |
| Stephanie Monaghan O'Brien | 女 | Director | 58 | 未披露 | 未持股 | 2017-11-09 |
| Cedric Francois | 男 | President, Chief Executive Officer and Director | 45 | 149.75万美元 | 未持股 | 2017-11-09 |
| Sinclair Dunlop | 男 | Director | 45 | 未披露 | 未持股 | 2017-11-09 |
| Robert Adelman | 男 | Director | 54 | 未披露 | 未持股 | 2017-11-09 |
| Bihua Chen | 女 | Director | 49 | 未披露 | 未持股 | 2017-11-09 |
| Maha Katabi | 女 | Director | 44 | 未披露 | 未持股 | 2017-11-09 |
| Alec Machiels | 男 | Director | 45 | 未披露 | 未持股 | 2017-11-09 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Timothy Sullivan | 男 | Chief Financial Officer and Treasurer | 47 | 未披露 | 未持股 | 2017-11-09 |
| Cedric Francois | 男 | President, Chief Executive Officer and Director | 45 | 149.75万美元 | 未持股 | 2017-11-09 |
| Pascal Deschatelets | 男 | Chief Operating Officer | 47 | 95.27万美元 | 未持股 | 2017-11-09 |
| Federico Grossi | 男 | Senior Vice President of Clinical Development | 43 | 未披露 | 未持股 | 2017-11-09 |
| Nicole Perry | 女 | Vice President Finance | 53 | 未披露 | 未持股 | 2017-11-09 |
| David Watson | 男 | General Counsel | 44 | 25.13万美元 | 未持股 | 2017-11-09 |
| Steven Axon | 男 | Chief Business Officer | 42 | 未披露 | 未持股 | 2017-11-09 |
董事简历
中英对照 | 中文 | 英文- Gerald Chan
-
Gerald Chan，2013年7月以来，他一直担任我们董事会的成员兼主席。他曾于1986年共同创立 Morningside公司（一个私人投资集团，涉及风险、私人股本和房地产投资）。他曾一直担任the International Society for Stem Cell Research的全球顾问委员会（2008年以来）、Harvard University的全球顾问委员会（2012年以来）、the Harvard School of Public Health的院长咨询委员会（2011年以来）、 the Cold Spring Harbor Conferences Asia的咨询委员会（2008年以来）、the Johns Hopkins Nanjing Center（2004年以来）、 the Columbia University Center for Radiological Research（2010年以来）的成员。他一直担任Hang Lung Group Limited公司（1986年以来）、Aduro Biotech公司（2014年以来）的董事会成员。他持有加利福尼亚大学洛杉矶分校（ the University of California, Los Angeles）的工程学士学位和硕士学位、Harvard University的医学放射物理硕士学位和放射生物学理学博士学位。他在the Dana-Farber Cancer Institute从事博士后研究，作为the Leukemia Society of America的成员。
Gerald Chan has served as a member of our board of directors since September 2020. Dr. Chan co-founded Morningside Venture Investments, Ltd., a private investment group with venture, private equity and property investments, in 1986. He has served as a member of Scientific Advisory Committee of Brigham and Women's Hospital since 2018 the Global Advisory Council of Harvard University since 2012 and the Dean's Board of Advisors of the Harvard T.H. Chan School of Public Health since 2011. and the advisory board of the Johns Hopkins Nanjing Center since 2004. He has served as trustee of Scripps Research Institute since 2016. Dr. Chan has served on the board of directors of Stealth BioTherapeutics Corp., a publicly traded biotechnology company, since 2007 and Apellis Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, since 2013. He has also been a member of the board of directors of Hang Lung Group Limited since 1986 and serves on the boards of several private companies. He previously chaired the Innovation Advisory Committee of Wellcome Trust from 2016 until 2020 and served as a director of Aduro Biotech Inc. from 2014 to 2018. Dr. Chan received his B.S. and M.S. degrees in engineering from the University of California, Los Angeles, and his Master's degree in medical radiological physics and Doctor of Science degree in radiation biology from Harvard University. He did his post-doctoral training at the Dana-Farber Cancer Institute. - Gerald Chan，2013年7月以来，他一直担任我们董事会的成员兼主席。他曾于1986年共同创立 Morningside公司（一个私人投资集团，涉及风险、私人股本和房地产投资）。他曾一直担任the International Society for Stem Cell Research的全球顾问委员会（2008年以来）、Harvard University的全球顾问委员会（2012年以来）、the Harvard School of Public Health的院长咨询委员会（2011年以来）、 the Cold Spring Harbor Conferences Asia的咨询委员会（2008年以来）、the Johns Hopkins Nanjing Center（2004年以来）、 the Columbia University Center for Radiological Research（2010年以来）的成员。他一直担任Hang Lung Group Limited公司（1986年以来）、Aduro Biotech公司（2014年以来）的董事会成员。他持有加利福尼亚大学洛杉矶分校（ the University of California, Los Angeles）的工程学士学位和硕士学位、Harvard University的医学放射物理硕士学位和放射生物学理学博士学位。他在the Dana-Farber Cancer Institute从事博士后研究，作为the Leukemia Society of America的成员。
- Gerald Chan has served as a member of our board of directors since September 2020. Dr. Chan co-founded Morningside Venture Investments, Ltd., a private investment group with venture, private equity and property investments, in 1986. He has served as a member of Scientific Advisory Committee of Brigham and Women's Hospital since 2018 the Global Advisory Council of Harvard University since 2012 and the Dean's Board of Advisors of the Harvard T.H. Chan School of Public Health since 2011. and the advisory board of the Johns Hopkins Nanjing Center since 2004. He has served as trustee of Scripps Research Institute since 2016. Dr. Chan has served on the board of directors of Stealth BioTherapeutics Corp., a publicly traded biotechnology company, since 2007 and Apellis Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, since 2013. He has also been a member of the board of directors of Hang Lung Group Limited since 1986 and serves on the boards of several private companies. He previously chaired the Innovation Advisory Committee of Wellcome Trust from 2016 until 2020 and served as a director of Aduro Biotech Inc. from 2014 to 2018. Dr. Chan received his B.S. and M.S. degrees in engineering from the University of California, Los Angeles, and his Master's degree in medical radiological physics and Doctor of Science degree in radiation biology from Harvard University. He did his post-doctoral training at the Dana-Farber Cancer Institute.
- Stephanie Monaghan O'Brien
-
Stephanie Monaghan O'Brien，自2011年起担任Apellis Pharmaceuticals，股份有限公司董事会成员。O'brian女士自1997年起担任Morningside投资团队的成员。她曾担任多家私营非临床和临床阶段公司的董事，开发涵盖广泛治疗重点的药物，包括肿瘤学和免疫治疗，并拥有丰富的经验，为风险投资支持的科技公司提供运营和管理监督。她还为Dendreon、BioVex、隐形生物治疗公司和Apellis Pharmaceutics，股份有限公司等公私公司提供了多项融资。在加入Morningside之前，O'brian女士在Hale和Dorr的波士顿和华盛顿特区办事处担任了九年的公司律师，主要从事公开募股、风险资本融资和初创公司的工作。她之前在大通曼哈顿银行工作，从事国际投资组合分析。她以优异成绩获得了哈佛大学的文学学士学位和纽约大学法学院的法学博士学位。
Stephanie Monaghan O'Brien has served as a member of Apellis Pharmaceuticals, Inc. Board of Directors since 2011. Ms. O'Brien has been a member of the investment team at Morningside since 1997. She has served as a director for numerous private nonclinical and clinical stage companies developing drugs across a broad spectrum of therapeutic focus, including oncology and immunotherapy, and has extensive experience providing operational and management oversight to venture-backed technology companies. She has also facilitated multiple financings for public and private companies such as Dendreon, BioVex, Stealth Biotherapeutics and Apellis Pharmaceuticals, Inc. Prior to joining Morningside, Ms. O'Brien spent nine years as a corporate lawyer with Hale and Dorr in the Boston and Washington, D.C. offices, working primarily on public offerings, venture capital finances and start-up companies. She previously worked at Chase Manhattan Bank, working in international portfolio analysis. She received her A.B., cum laude, from Harvard College and her J.D. from New York University School of Law. - Stephanie Monaghan O'Brien，自2011年起担任Apellis Pharmaceuticals，股份有限公司董事会成员。O'brian女士自1997年起担任Morningside投资团队的成员。她曾担任多家私营非临床和临床阶段公司的董事，开发涵盖广泛治疗重点的药物，包括肿瘤学和免疫治疗，并拥有丰富的经验，为风险投资支持的科技公司提供运营和管理监督。她还为Dendreon、BioVex、隐形生物治疗公司和Apellis Pharmaceutics，股份有限公司等公私公司提供了多项融资。在加入Morningside之前，O'brian女士在Hale和Dorr的波士顿和华盛顿特区办事处担任了九年的公司律师，主要从事公开募股、风险资本融资和初创公司的工作。她之前在大通曼哈顿银行工作，从事国际投资组合分析。她以优异成绩获得了哈佛大学的文学学士学位和纽约大学法学院的法学博士学位。
- Stephanie Monaghan O'Brien has served as a member of Apellis Pharmaceuticals, Inc. Board of Directors since 2011. Ms. O'Brien has been a member of the investment team at Morningside since 1997. She has served as a director for numerous private nonclinical and clinical stage companies developing drugs across a broad spectrum of therapeutic focus, including oncology and immunotherapy, and has extensive experience providing operational and management oversight to venture-backed technology companies. She has also facilitated multiple financings for public and private companies such as Dendreon, BioVex, Stealth Biotherapeutics and Apellis Pharmaceuticals, Inc. Prior to joining Morningside, Ms. O'Brien spent nine years as a corporate lawyer with Hale and Dorr in the Boston and Washington, D.C. offices, working primarily on public offerings, venture capital finances and start-up companies. She previously worked at Chase Manhattan Bank, working in international portfolio analysis. She received her A.B., cum laude, from Harvard College and her J.D. from New York University School of Law.
- Cedric Francois
-
Cedric Francois，本公司的共同创始人；自2009年9月起，担任本公司的董事、总裁、首席执行官。参与创办本公司之前，他是Potentia Pharmaceuticals, Inc.的共同创始人，这是一个私营的生物技术公司，本公司在2015年9月收购了其资产。他从2001年起，担任Potentia的总裁、首席执行官；2003年起，担任其董事。他在比利时的 University of Leuven获得医学博士学位，在University of Louisville获得生理学博士学位。完成儿科和移植手术研究生实习之后，他成为了成功完成首例手臂移植手术的团队成员，以及Louisville Face Transplant Team的成员，该团队在2005年协助了法国里昂的手臂移植手术。
Cedric Francois, M.D., Ph.D., is a co-founder of our company and has served as a member of our board of directors and as our President and Chief Executive Officer since our inception. Prior to co-founding our company, Dr. Francois co-founded Potentia Pharmaceuticals, Inc., or Potentia, a private biotechnology company, the assets of which we purchased in September 2015. Dr. Francois has served as President and Chief Executive Officer at Potentia since 2001 and has served as a director of Potentia since 2003. Dr. Francois received his M.D. from the University of Leuven in Belgium and his Ph.D. in physiology from the University of Louisville. Following postgraduate training in pediatric and transplant surgery, Dr. Francois was a member of the research team that performed the first successful hand transplantation and of the Louisville Face Transplant Team, whose work supported hand transplantation in Lyon, France. - Cedric Francois，本公司的共同创始人；自2009年9月起，担任本公司的董事、总裁、首席执行官。参与创办本公司之前，他是Potentia Pharmaceuticals, Inc.的共同创始人，这是一个私营的生物技术公司，本公司在2015年9月收购了其资产。他从2001年起，担任Potentia的总裁、首席执行官；2003年起，担任其董事。他在比利时的 University of Leuven获得医学博士学位，在University of Louisville获得生理学博士学位。完成儿科和移植手术研究生实习之后，他成为了成功完成首例手臂移植手术的团队成员，以及Louisville Face Transplant Team的成员，该团队在2005年协助了法国里昂的手臂移植手术。
- Cedric Francois, M.D., Ph.D., is a co-founder of our company and has served as a member of our board of directors and as our President and Chief Executive Officer since our inception. Prior to co-founding our company, Dr. Francois co-founded Potentia Pharmaceuticals, Inc., or Potentia, a private biotechnology company, the assets of which we purchased in September 2015. Dr. Francois has served as President and Chief Executive Officer at Potentia since 2001 and has served as a director of Potentia since 2003. Dr. Francois received his M.D. from the University of Leuven in Belgium and his Ph.D. in physiology from the University of Louisville. Following postgraduate training in pediatric and transplant surgery, Dr. Francois was a member of the research team that performed the first successful hand transplantation and of the Louisville Face Transplant Team, whose work supported hand transplantation in Lyon, France.
- Sinclair Dunlop
-
Sinclair Dunlop，2010年3月起，担任本公司董事。他现为风投基金Epidarex Capital的共同创始人，自2010年7月起，担任管理合伙人。2005年起，他担任风投基金Masa Life Science Ventures, LP的管理合伙人。他现为一些私营企业的董事，其中包括Potentia。他在Columbia Business School获得工商管理硕士学位，曾是国际商业的R.C. Kopf British-American Fellow；还在University of Glasgow获得政治经济荣誉硕士学位，在Maxwell School of Citizenship and Public Affairs at Syracuse University获得国际关系硕士学位。
Sinclair Dunlop has served as a member of our board of directors since March 2010. Mr. Dunlop is a co-founder of venture capital fund Epidarex Capital, and has served as the Managing Partner since July 2010. Since 2005 Mr. Dunlop has served as the Managing Partner of venture capital fund Masa Life Science Ventures, LP. Mr. Dunlop currently serves on the board of directors of several private companies, including Potentia. Mr. Dunlop received his M.B.A. from Columbia Business School where he was the R.C. Kopf British-American Fellow in international business. He also received an M.A. with Honors in political economy from the University of Glasgow and an M.A. in international relations from the Maxwell School of Citizenship and Public Affairs at Syracuse University. - Sinclair Dunlop，2010年3月起，担任本公司董事。他现为风投基金Epidarex Capital的共同创始人，自2010年7月起，担任管理合伙人。2005年起，他担任风投基金Masa Life Science Ventures, LP的管理合伙人。他现为一些私营企业的董事，其中包括Potentia。他在Columbia Business School获得工商管理硕士学位，曾是国际商业的R.C. Kopf British-American Fellow；还在University of Glasgow获得政治经济荣誉硕士学位，在Maxwell School of Citizenship and Public Affairs at Syracuse University获得国际关系硕士学位。
- Sinclair Dunlop has served as a member of our board of directors since March 2010. Mr. Dunlop is a co-founder of venture capital fund Epidarex Capital, and has served as the Managing Partner since July 2010. Since 2005 Mr. Dunlop has served as the Managing Partner of venture capital fund Masa Life Science Ventures, LP. Mr. Dunlop currently serves on the board of directors of several private companies, including Potentia. Mr. Dunlop received his M.B.A. from Columbia Business School where he was the R.C. Kopf British-American Fellow in international business. He also received an M.A. with Honors in political economy from the University of Glasgow and an M.A. in international relations from the Maxwell School of Citizenship and Public Affairs at Syracuse University.
- Robert Adelman
-
Robert Adelman自2015年1月以来一直担任我们的董事会成员。他曾一直担任Venbio Partners公司（生命科学投资公司，他于2009年共同创立的公司）的管理合伙人（2010年以来）。共同创立Venbio公司之前，他曾任职OrbiMed Advisors公司（从2002年到2008年），在那里他曾领导三个风险投资基金的私人和上市公司的多种投资。此外，Adelman博士还曾在ApellisPharmaceuticals，Inc.、Turning PointTherapeutics，Inc.、Seragon和Aragon的董事会任职。Adelman博士在加州大学伯克利分校（University of California at Berkeley）获得学士学位，在耶鲁大学（Yale University）获得医学博士学位，在康奈尔大学医学中心（Cornell University Medical Center）进行住院实习，并在纽约和新泽西从事外科手术。
Robert Adelman has served as a member of our board of directors since January 2015. Since 2010 Dr. Adelman has served as Managing Partner at venBio Partners LLC, or venBio, a life sciences investment firm, which he co-founded in 2009. Prior to co-founding venBio, Dr. Adelman worked at OrbiMed Advisors LLC from 2002 to 2008 where he led numerous investments in both private and public companies across three venture capital funds. In addition, Dr. Adelman previously served on the boards of directors of Apellis Pharmaceuticals, Inc., Turning Point Therapeutics, Inc., Seragon and Aragon. Dr. Adelman received his B.A. from University of California at Berkeley and his M.D. from Yale University, performed his residency at Cornell University Medical Center, and practiced surgery in New York and New Jersey. - Robert Adelman自2015年1月以来一直担任我们的董事会成员。他曾一直担任Venbio Partners公司（生命科学投资公司，他于2009年共同创立的公司）的管理合伙人（2010年以来）。共同创立Venbio公司之前，他曾任职OrbiMed Advisors公司（从2002年到2008年），在那里他曾领导三个风险投资基金的私人和上市公司的多种投资。此外，Adelman博士还曾在ApellisPharmaceuticals，Inc.、Turning PointTherapeutics，Inc.、Seragon和Aragon的董事会任职。Adelman博士在加州大学伯克利分校（University of California at Berkeley）获得学士学位，在耶鲁大学（Yale University）获得医学博士学位，在康奈尔大学医学中心（Cornell University Medical Center）进行住院实习，并在纽约和新泽西从事外科手术。
- Robert Adelman has served as a member of our board of directors since January 2015. Since 2010 Dr. Adelman has served as Managing Partner at venBio Partners LLC, or venBio, a life sciences investment firm, which he co-founded in 2009. Prior to co-founding venBio, Dr. Adelman worked at OrbiMed Advisors LLC from 2002 to 2008 where he led numerous investments in both private and public companies across three venture capital funds. In addition, Dr. Adelman previously served on the boards of directors of Apellis Pharmaceuticals, Inc., Turning Point Therapeutics, Inc., Seragon and Aragon. Dr. Adelman received his B.A. from University of California at Berkeley and his M.D. from Yale University, performed his residency at Cornell University Medical Center, and practiced surgery in New York and New Jersey.
- Bihua Chen
-
Bihua Chen自2020年12月以来一直担任我们的董事会成员。Chen女士是Cormorant Asset Management，LP的创始人，该公司是一家投资公司，专注于创新生物技术，医疗技术和生命科学公司，并自2013年2月成立以来管理Cormorant’；s对冲基金及其私募股权基金。创立Cormorant之前，Chen从2005年到2010年担任Millennium Management LLC（一家多策略对冲基金）副顾问。此前，从2001年到2002年，陈女士是投资顾问美国运通资产管理公司（American Express Asset Management）的梦百合分析师和行业组合经理。陈女士还曾于2001年至2002年担任Asterion Life Science Fund的投资组合经理，2000年至2001年担任Bellevue Research的股票分析师和投资组合经理，1998年至2001年担任Putnam Investments的股票分析师。陈女士目前在Atia Vision，U.S.（一家私人持有的医疗创新枢纽）的董事会任职。陈女士拥有中国上海复旦大学遗传学和基因工程学士学位，康奈尔医学院生物医学科学研究生院分子生物学硕士学位和沃顿商学院工商管理硕士学位。
Bihua Chen,is the founder and managing member of Cormorant. Ms. Chen was the Chief Executive Officer and Chairwoman of Helix I from its inception until April 2022, when Helix I completed its business combination with MoonLake. From 2020 to July 2025, Ms. Chen served as a director of Biomea Fusion, Inc. (Nasdaq: BMEA). Prior to founding Cormorant in 2013, Ms. Chen managed a separately managed account focused on the healthcare sector as a sub-adviser to a large, multi-strategy hedge fund based in New York. Prior to that, Ms. Chen was a healthcare analyst and sector portfolio manager for American Express Asset Management, Boston. Ms. Chen has also served as a portfolio manager for the Asterion Life Science Fund from 2001 through 2002, an equity analyst and portfolio manager for Bellevue Research from 2000 through 2001 and an equity analyst for Putnam Investments from 1998 through 2001. Ms. Chen obtained a Master of Business Administration degree from the Wharton School of Business in 1998 and graduated with a Master of Science degree in Molecular Biology from the Graduate School of Biomedical Science at Cornell Medical College in 1994. Ms. Chen also holds a Bachelor of Science degree in Genetics and Genetic Engineering from Fudan University, Shanghai, China, which she received in 1990. - Bihua Chen自2020年12月以来一直担任我们的董事会成员。Chen女士是Cormorant Asset Management，LP的创始人，该公司是一家投资公司，专注于创新生物技术，医疗技术和生命科学公司，并自2013年2月成立以来管理Cormorant’；s对冲基金及其私募股权基金。创立Cormorant之前，Chen从2005年到2010年担任Millennium Management LLC（一家多策略对冲基金）副顾问。此前，从2001年到2002年，陈女士是投资顾问美国运通资产管理公司（American Express Asset Management）的梦百合分析师和行业组合经理。陈女士还曾于2001年至2002年担任Asterion Life Science Fund的投资组合经理，2000年至2001年担任Bellevue Research的股票分析师和投资组合经理，1998年至2001年担任Putnam Investments的股票分析师。陈女士目前在Atia Vision，U.S.（一家私人持有的医疗创新枢纽）的董事会任职。陈女士拥有中国上海复旦大学遗传学和基因工程学士学位，康奈尔医学院生物医学科学研究生院分子生物学硕士学位和沃顿商学院工商管理硕士学位。
- Bihua Chen,is the founder and managing member of Cormorant. Ms. Chen was the Chief Executive Officer and Chairwoman of Helix I from its inception until April 2022, when Helix I completed its business combination with MoonLake. From 2020 to July 2025, Ms. Chen served as a director of Biomea Fusion, Inc. (Nasdaq: BMEA). Prior to founding Cormorant in 2013, Ms. Chen managed a separately managed account focused on the healthcare sector as a sub-adviser to a large, multi-strategy hedge fund based in New York. Prior to that, Ms. Chen was a healthcare analyst and sector portfolio manager for American Express Asset Management, Boston. Ms. Chen has also served as a portfolio manager for the Asterion Life Science Fund from 2001 through 2002, an equity analyst and portfolio manager for Bellevue Research from 2000 through 2001 and an equity analyst for Putnam Investments from 1998 through 2001. Ms. Chen obtained a Master of Business Administration degree from the Wharton School of Business in 1998 and graduated with a Master of Science degree in Molecular Biology from the Graduate School of Biomedical Science at Cornell Medical College in 1994. Ms. Chen also holds a Bachelor of Science degree in Genetics and Genetic Engineering from Fudan University, Shanghai, China, which she received in 1990.
- Maha Katabi
-
Maha Katabi，自2022年8月起担任Rayzebio，Inc.董事会成员。Katabi博士于2019年4月作为合伙人加入生物技术投资公司Sofinnova Investments，自2020年3月起担任普通合伙人。此前，卡塔比博士曾于2018年8月至2019年4月担任风险投资公司Oxalis Capital的创始管理合伙人。从2008年9月到2018年1月，卡塔比博士在Sectoral Asset Management担任投资经理，后来成为私人股本合伙人。Sectoral Asset Management是一家专注于全球医疗保健领域的投资顾问，她是投资于小型和私人生物技术公司的一系列基金的投资组合经理。在加入Sectoral之前，Katabi博士从2004年到2008年在Ventures West担任副总裁，在那里她专注于生命科学行业的早期风险投资。1999年，她在专注于大学初创企业的种子基金T2C2 Capital Bio开始了她的风险投资生涯。卡塔比博士从2021年3月起担任Gyroscope Therapeutics的董事会成员，直到2022年2月被诺华收购；从2020年5月起担任Amplyx Pharmaceuticals的董事会成员，直到2021年4月被辉瑞收购。Katabi博士目前是Aerovate Therapeutics, Inc.、Quanta Therapeutics公司、Sofinnova Investments公司和Vera Therapeutics公司的董事会成员。Aerovate Therapeutics公司是一家上市的临床阶段生物制药公司。她是Exactis Innovation的董事会主席，Exactis Innovation是一家非营利的泛加拿大精准肿瘤研究网络，也是Yale Ventures旗下AmplifyHERscience的顾问。Katabi博士在麦吉尔大学获得药理学博士学位和生物学学士学位，并于2011年获得CFA证书。
Maha Katabi,has served as a member of Board since October 2020. Dr. Katabi joined Sofinnova Investments, a venture capital firm, in April 2019 as a Partner and has been a General Partner since March 2020. Previously, Dr. Katabi was a founding Managing Partner at Oxalis Capital, a venture capital firm, from August 2018 until April 2019. From September 2008 until January 2018, Dr. Katabi was an Investment Manager and later Partner, Private Equity at Sectoral Asset Management, an investment advisor exclusively focused on the global healthcare sector, where she was the portfolio manager of a family of funds investing in small cap and private biotech companies. Prior to joining Sectoral, Dr. Katabi was a Vice President at Ventures West, a venture capital firm, from 2004 to 2008, where she focused on early-stage venture investments in the life sciences industry. She started her venture capital career in 1999 with T2C2 Capital Bio, a seed fund focused on university start-ups. Dr. Katabi was a member of the board of directors of Gyroscope Therapeutics Limited, a gene therapy company, from March 2021 until it was acquired by Novartis AG ("Novartis") in February 2022, and a member of the board of directors of Amplyx Pharmaceuticals, Inc., biopharmaceutical company, from May 2020 until it was acquired by Pfizer Inc. (NYSE: PFE) ("Pfizer") in April 2021, Aiolos Bio, Inc., a biopharmaceutical company, from September 2023 until it was acquired in February 2024 by GSK plc ("GSK"), Aerovate Therapeutics Inc. (Nasdaq: AVTE), a biotechnology company from August 2020 to September 2024, Rayze Bio, Inc. (Nasdaq: RYZB), a biotechnology company, from August 2022 until it was acquired in February 2024 by Bristol Meyers Squibb, and Northsea Therapeutics, B.V. from March 2019 to June 2021. Dr. Katabi currently serves as a member of the board of directors of Quanta Therapeutics, Inc., a biotechnology company, since June 2021, Star Therapeutics, Inc., since June 2023 and Sofinnova Investments. She serves as Chairman of the board of directors of Exactis Innovation, a not-for-profit pan-Canadian research network for precision oncology, and an advisor to amplifyHERscience, a Yale Ventures program dedicated to supporting and promoting science and entrepreneurial pursuits. Dr. Katabi received a Ph.D. in Pharmacology and a B.Sc. in Biology at McGill University and her CFA charter in 2011. - Maha Katabi，自2022年8月起担任Rayzebio，Inc.董事会成员。Katabi博士于2019年4月作为合伙人加入生物技术投资公司Sofinnova Investments，自2020年3月起担任普通合伙人。此前，卡塔比博士曾于2018年8月至2019年4月担任风险投资公司Oxalis Capital的创始管理合伙人。从2008年9月到2018年1月，卡塔比博士在Sectoral Asset Management担任投资经理，后来成为私人股本合伙人。Sectoral Asset Management是一家专注于全球医疗保健领域的投资顾问，她是投资于小型和私人生物技术公司的一系列基金的投资组合经理。在加入Sectoral之前，Katabi博士从2004年到2008年在Ventures West担任副总裁，在那里她专注于生命科学行业的早期风险投资。1999年，她在专注于大学初创企业的种子基金T2C2 Capital Bio开始了她的风险投资生涯。卡塔比博士从2021年3月起担任Gyroscope Therapeutics的董事会成员，直到2022年2月被诺华收购；从2020年5月起担任Amplyx Pharmaceuticals的董事会成员，直到2021年4月被辉瑞收购。Katabi博士目前是Aerovate Therapeutics, Inc.、Quanta Therapeutics公司、Sofinnova Investments公司和Vera Therapeutics公司的董事会成员。Aerovate Therapeutics公司是一家上市的临床阶段生物制药公司。她是Exactis Innovation的董事会主席，Exactis Innovation是一家非营利的泛加拿大精准肿瘤研究网络，也是Yale Ventures旗下AmplifyHERscience的顾问。Katabi博士在麦吉尔大学获得药理学博士学位和生物学学士学位，并于2011年获得CFA证书。
- Maha Katabi,has served as a member of Board since October 2020. Dr. Katabi joined Sofinnova Investments, a venture capital firm, in April 2019 as a Partner and has been a General Partner since March 2020. Previously, Dr. Katabi was a founding Managing Partner at Oxalis Capital, a venture capital firm, from August 2018 until April 2019. From September 2008 until January 2018, Dr. Katabi was an Investment Manager and later Partner, Private Equity at Sectoral Asset Management, an investment advisor exclusively focused on the global healthcare sector, where she was the portfolio manager of a family of funds investing in small cap and private biotech companies. Prior to joining Sectoral, Dr. Katabi was a Vice President at Ventures West, a venture capital firm, from 2004 to 2008, where she focused on early-stage venture investments in the life sciences industry. She started her venture capital career in 1999 with T2C2 Capital Bio, a seed fund focused on university start-ups. Dr. Katabi was a member of the board of directors of Gyroscope Therapeutics Limited, a gene therapy company, from March 2021 until it was acquired by Novartis AG ("Novartis") in February 2022, and a member of the board of directors of Amplyx Pharmaceuticals, Inc., biopharmaceutical company, from May 2020 until it was acquired by Pfizer Inc. (NYSE: PFE) ("Pfizer") in April 2021, Aiolos Bio, Inc., a biopharmaceutical company, from September 2023 until it was acquired in February 2024 by GSK plc ("GSK"), Aerovate Therapeutics Inc. (Nasdaq: AVTE), a biotechnology company from August 2020 to September 2024, Rayze Bio, Inc. (Nasdaq: RYZB), a biotechnology company, from August 2022 until it was acquired in February 2024 by Bristol Meyers Squibb, and Northsea Therapeutics, B.V. from March 2019 to June 2021. Dr. Katabi currently serves as a member of the board of directors of Quanta Therapeutics, Inc., a biotechnology company, since June 2021, Star Therapeutics, Inc., since June 2023 and Sofinnova Investments. She serves as Chairman of the board of directors of Exactis Innovation, a not-for-profit pan-Canadian research network for precision oncology, and an advisor to amplifyHERscience, a Yale Ventures program dedicated to supporting and promoting science and entrepreneurial pursuits. Dr. Katabi received a Ph.D. in Pharmacology and a B.Sc. in Biology at McGill University and her CFA charter in 2011.
- Alec Machiels
-
Alec Machiels， 从2008年9月开始担任董事。从2006年5月开始，他一直担任私人股本基金管理公司，Pegasus咨询有限合伙公司的合伙人。在成为Pegasus的合伙人之前，他从2004年6月至2006年5月一直担任副总裁，从2002年8月至2004年6月是合作伙伴。从2003年至2005年，他是Coffeyville资源有限责任公司董事会成员，这是一家位于凯萨斯州科菲维尔的炼油厂和氨机房。从2005年至2010年，他是Merisant全球有限公司的董事会成员，该公司是代糖甜味剂的生产商和分销商。自2006年1月，他任职于Traxys S.A.公司的董事会，这是一家金属贸易和经销公司。他在伦敦高盛国际（Goldman Sachs International）金融服务部门担任财务分析师，开始了他的职业生涯。从1996年7月至1999年6月，他在纽约高盛公司（Goldman, Sachs & Co。）私人股权部任职。从2001年7月至2002年7月，他在Potentia制药有限公司担任首席执行官兼主席。Machiels先生于2001年在哈佛商学院（Harvard Business School）获得了工商管理硕士学位。他还在比利时鲁汶法学院（KU Leuven Law School）获得了法学硕士学位，在德国康斯坦茨（Konstanz University）大学获得了国际经济学硕士学位。
Alec Machiels is a Partner at Pegasus Capital Advisors, L.P., a private equity fund manager, and joined our Board of Directors in August 2014 in connection with our acquisition of Creative Realities, LLC. Mr. Machiels is a member of the Executive, Investment and Sustainability Committees, as well as the co-chair of the Energy and Wellness Committees at Pegasus Capital Advisors, L.P. Previously, Mr. Machiels was a Financial Analyst in the Financial Services Group at Goldman Sachs International in London and in the Private Equity Group at Goldman Sachs and Co. in New York. Investments in which he has been highly involved in include Molycorp Minerals, Traxys, Pure Biofuels, Olympus, Slipstream Communications, Coffeyville Resources and Merisant Company. Mr. Machiels previously served on the board of Pure Biofuels from 2012-2018 and currently serves on the boards of Olympus, Slipstream Communications, NSI, and Valogix. He was also a member of the Board of Trustees of the American Federation of Arts and Chair of its Endowment Committee 2011- 2013. Mr. Machiels also co-founded Potentia Pharmaceuticals and Apellis Pharmaceuticals - two biotechnology companies in the complement immunotherapy space - as well as Revon Systems, a healthcare IT company. Mr. Machiels is a graduate of Harvard Business School, KU Leuven Law School in Belgium and Konstanz University in Germany. - Alec Machiels， 从2008年9月开始担任董事。从2006年5月开始，他一直担任私人股本基金管理公司，Pegasus咨询有限合伙公司的合伙人。在成为Pegasus的合伙人之前，他从2004年6月至2006年5月一直担任副总裁，从2002年8月至2004年6月是合作伙伴。从2003年至2005年，他是Coffeyville资源有限责任公司董事会成员，这是一家位于凯萨斯州科菲维尔的炼油厂和氨机房。从2005年至2010年，他是Merisant全球有限公司的董事会成员，该公司是代糖甜味剂的生产商和分销商。自2006年1月，他任职于Traxys S.A.公司的董事会，这是一家金属贸易和经销公司。他在伦敦高盛国际（Goldman Sachs International）金融服务部门担任财务分析师，开始了他的职业生涯。从1996年7月至1999年6月，他在纽约高盛公司（Goldman, Sachs & Co。）私人股权部任职。从2001年7月至2002年7月，他在Potentia制药有限公司担任首席执行官兼主席。Machiels先生于2001年在哈佛商学院（Harvard Business School）获得了工商管理硕士学位。他还在比利时鲁汶法学院（KU Leuven Law School）获得了法学硕士学位，在德国康斯坦茨（Konstanz University）大学获得了国际经济学硕士学位。
- Alec Machiels is a Partner at Pegasus Capital Advisors, L.P., a private equity fund manager, and joined our Board of Directors in August 2014 in connection with our acquisition of Creative Realities, LLC. Mr. Machiels is a member of the Executive, Investment and Sustainability Committees, as well as the co-chair of the Energy and Wellness Committees at Pegasus Capital Advisors, L.P. Previously, Mr. Machiels was a Financial Analyst in the Financial Services Group at Goldman Sachs International in London and in the Private Equity Group at Goldman Sachs and Co. in New York. Investments in which he has been highly involved in include Molycorp Minerals, Traxys, Pure Biofuels, Olympus, Slipstream Communications, Coffeyville Resources and Merisant Company. Mr. Machiels previously served on the board of Pure Biofuels from 2012-2018 and currently serves on the boards of Olympus, Slipstream Communications, NSI, and Valogix. He was also a member of the Board of Trustees of the American Federation of Arts and Chair of its Endowment Committee 2011- 2013. Mr. Machiels also co-founded Potentia Pharmaceuticals and Apellis Pharmaceuticals - two biotechnology companies in the complement immunotherapy space - as well as Revon Systems, a healthcare IT company. Mr. Machiels is a graduate of Harvard Business School, KU Leuven Law School in Belgium and Konstanz University in Germany.
高管简历
中英对照 | 中文 | 英文- Timothy Sullivan
Timothy Sullivan自2017年10月起担任我们的首席财务官兼财务主管。2014年1月至2017年10月，沙利文先生担任风险投资公司AJU IB Investment的合伙人，领导该公司对生命科学公司的投资。在加入AJU IB Investment之前，2011年12月至2014年1月，Sullivan先生是RBS Citizens的董事总经理，生命科学主管。Sullivan先生于2014年11月至2017年10月担任我们董事会的观察员。Sullivan先生此前曾担任G1治疗公司和MolecularTemplates，Inc.的董事。Sullivan先生在哥伦比亚商学院（Columbia Business School）获得工商管理硕士学位，在哈佛大学（Harvard University）获得生物学学士学位。
Timothy Sullivan has served as our Chief Financial Officer and Treasurer since October 2017. From January 2014 to October 2017, Mr. Sullivan served as Partner at AJU IB Investment, a venture capital firm, at which he led the firm's investments in life sciences companies. Prior to joining AJU IB Investment, from December 2011 to January 2014, Mr. Sullivan was Managing Director, Head of Life Sciences at RBS Citizens. Mr. Sullivan was an observer on our board of directors from November 2014 until October 2017. Mr. Sullivan has previously served as a director of G1 Therapeutics, Inc. and Molecular Templates, Inc. Mr. Sullivan received his M.B.A. from the Columbia Business School and his B.A. in Biology from Harvard University.- Timothy Sullivan自2017年10月起担任我们的首席财务官兼财务主管。2014年1月至2017年10月，沙利文先生担任风险投资公司AJU IB Investment的合伙人，领导该公司对生命科学公司的投资。在加入AJU IB Investment之前，2011年12月至2014年1月，Sullivan先生是RBS Citizens的董事总经理，生命科学主管。Sullivan先生于2014年11月至2017年10月担任我们董事会的观察员。Sullivan先生此前曾担任G1治疗公司和MolecularTemplates，Inc.的董事。Sullivan先生在哥伦比亚商学院（Columbia Business School）获得工商管理硕士学位，在哈佛大学（Harvard University）获得生物学学士学位。
- Timothy Sullivan has served as our Chief Financial Officer and Treasurer since October 2017. From January 2014 to October 2017, Mr. Sullivan served as Partner at AJU IB Investment, a venture capital firm, at which he led the firm's investments in life sciences companies. Prior to joining AJU IB Investment, from December 2011 to January 2014, Mr. Sullivan was Managing Director, Head of Life Sciences at RBS Citizens. Mr. Sullivan was an observer on our board of directors from November 2014 until October 2017. Mr. Sullivan has previously served as a director of G1 Therapeutics, Inc. and Molecular Templates, Inc. Mr. Sullivan received his M.B.A. from the Columbia Business School and his B.A. in Biology from Harvard University.
- Cedric Francois
Cedric Francois，本公司的共同创始人；自2009年9月起，担任本公司的董事、总裁、首席执行官。参与创办本公司之前，他是Potentia Pharmaceuticals, Inc.的共同创始人，这是一个私营的生物技术公司，本公司在2015年9月收购了其资产。他从2001年起，担任Potentia的总裁、首席执行官；2003年起，担任其董事。他在比利时的 University of Leuven获得医学博士学位，在University of Louisville获得生理学博士学位。完成儿科和移植手术研究生实习之后，他成为了成功完成首例手臂移植手术的团队成员，以及Louisville Face Transplant Team的成员，该团队在2005年协助了法国里昂的手臂移植手术。
Cedric Francois, M.D., Ph.D., is a co-founder of our company and has served as a member of our board of directors and as our President and Chief Executive Officer since our inception. Prior to co-founding our company, Dr. Francois co-founded Potentia Pharmaceuticals, Inc., or Potentia, a private biotechnology company, the assets of which we purchased in September 2015. Dr. Francois has served as President and Chief Executive Officer at Potentia since 2001 and has served as a director of Potentia since 2003. Dr. Francois received his M.D. from the University of Leuven in Belgium and his Ph.D. in physiology from the University of Louisville. Following postgraduate training in pediatric and transplant surgery, Dr. Francois was a member of the research team that performed the first successful hand transplantation and of the Louisville Face Transplant Team, whose work supported hand transplantation in Lyon, France.- Cedric Francois，本公司的共同创始人；自2009年9月起，担任本公司的董事、总裁、首席执行官。参与创办本公司之前，他是Potentia Pharmaceuticals, Inc.的共同创始人，这是一个私营的生物技术公司，本公司在2015年9月收购了其资产。他从2001年起，担任Potentia的总裁、首席执行官；2003年起，担任其董事。他在比利时的 University of Leuven获得医学博士学位，在University of Louisville获得生理学博士学位。完成儿科和移植手术研究生实习之后，他成为了成功完成首例手臂移植手术的团队成员，以及Louisville Face Transplant Team的成员，该团队在2005年协助了法国里昂的手臂移植手术。
- Cedric Francois, M.D., Ph.D., is a co-founder of our company and has served as a member of our board of directors and as our President and Chief Executive Officer since our inception. Prior to co-founding our company, Dr. Francois co-founded Potentia Pharmaceuticals, Inc., or Potentia, a private biotechnology company, the assets of which we purchased in September 2015. Dr. Francois has served as President and Chief Executive Officer at Potentia since 2001 and has served as a director of Potentia since 2003. Dr. Francois received his M.D. from the University of Leuven in Belgium and his Ph.D. in physiology from the University of Louisville. Following postgraduate training in pediatric and transplant surgery, Dr. Francois was a member of the research team that performed the first successful hand transplantation and of the Louisville Face Transplant Team, whose work supported hand transplantation in Lyon, France.
- Pascal Deschatelets
Pascal Deschatelets，本公司的联合创始人；自2009年9月起，担任首席运营官。他还曾参与创办Potentia，并自2001年起，担任首席运营官。他在University of Montreal获得有机化学博士学位，在Harvard University的Dr. George Whitesides实验室进行博士后实习。
Pascal Deschatelets, Ph.D., is a co-founder of our company and has served as our Chief Operating Officer since our inception. Dr. Deschatelets also co-founded Potentia and served as its Chief Operating Officer from 2001 to September 2016. Dr. Deschatelets received his Ph.D. in organic chemistry from the University of Montreal and his post-doctoral training in the laboratory of Dr. George Whitesides at Harvard University.- Pascal Deschatelets，本公司的联合创始人；自2009年9月起，担任首席运营官。他还曾参与创办Potentia，并自2001年起，担任首席运营官。他在University of Montreal获得有机化学博士学位，在Harvard University的Dr. George Whitesides实验室进行博士后实习。
- Pascal Deschatelets, Ph.D., is a co-founder of our company and has served as our Chief Operating Officer since our inception. Dr. Deschatelets also co-founded Potentia and served as its Chief Operating Officer from 2001 to September 2016. Dr. Deschatelets received his Ph.D. in organic chemistry from the University of Montreal and his post-doctoral training in the laboratory of Dr. George Whitesides at Harvard University.
- Federico Grossi
Federico Grossi，2014年10月起，担任本公司的临床开发副总裁；此前，2010年4月至2012年6月，担任临床研究总监。2013年10月至2014年9月，他担任Potentia的执行副总裁；2006年至2010年4月，担任临床研究总监。2012年6月至12月，他是早期阶段临床研究的独立顾问。他在阿根廷的 University of Córdoba获得医学博士学位，在University of Louisville获得生理学博士学位。他完成了外科的研究生培训，获得了显微外科、复合组合移植方面的专业知识；此后，他加入了Plastic Surgery Research Laboratory at the University of Louisville。
Federico Grossi, M.D., Ph.D. has served as our Senior Vice President of Clinical Development since October 2017 having previously served as our Vice President of Clinical Development from October 2014 to October 2017 and as our Clinical Research Director from April 2010 to June 2012. Dr. Grossi served as Executive Vice President of Potentia from October 2013 to September 2014 and as Clinical Research Director of Potentia from 2006 to April 2010. From June 2012 to October 2014 Dr. Grossi worked as an independent early stage clinical research consultant. Dr. Grossi received his M.D. from the University of Córdoba in Argentina and his Ph.D. in physiology from the University of Louisville. Following his post-graduate training in surgery, where he developed his expertise in microsurgery and composite tissue transplantation, Dr. Grossi joined the Plastic Surgery Research Laboratory at the University of Louisville.- Federico Grossi，2014年10月起，担任本公司的临床开发副总裁；此前，2010年4月至2012年6月，担任临床研究总监。2013年10月至2014年9月，他担任Potentia的执行副总裁；2006年至2010年4月，担任临床研究总监。2012年6月至12月，他是早期阶段临床研究的独立顾问。他在阿根廷的 University of Córdoba获得医学博士学位，在University of Louisville获得生理学博士学位。他完成了外科的研究生培训，获得了显微外科、复合组合移植方面的专业知识；此后，他加入了Plastic Surgery Research Laboratory at the University of Louisville。
- Federico Grossi, M.D., Ph.D. has served as our Senior Vice President of Clinical Development since October 2017 having previously served as our Vice President of Clinical Development from October 2014 to October 2017 and as our Clinical Research Director from April 2010 to June 2012. Dr. Grossi served as Executive Vice President of Potentia from October 2013 to September 2014 and as Clinical Research Director of Potentia from 2006 to April 2010. From June 2012 to October 2014 Dr. Grossi worked as an independent early stage clinical research consultant. Dr. Grossi received his M.D. from the University of Córdoba in Argentina and his Ph.D. in physiology from the University of Louisville. Following his post-graduate training in surgery, where he developed his expertise in microsurgery and composite tissue transplantation, Dr. Grossi joined the Plastic Surgery Research Laboratory at the University of Louisville.
- Nicole Perry
Nicole Perry，2015年4月起，担任本公司的财务副总裁。2015年4月至2015年6月，她还担任Revon Systems, LLC的财务副总裁，这是私营的健康护理技术平台公司。2000年8月至2015年4月，她是一名独立顾问，主要为客户提供财务报告 、内部风控合规领域的服务，也是外部会计师、银行家、法律顾问的联络人。拥有自己的顾问公司之前，她在PriceWaterhouseCoopers、Deloitte从事审计工作。她是注册会计师，以优异成绩在University of Oklahoma获得会计方向的工商管理学士学位。
Nicole Perry has served as our Vice President of Finance since April 2015. From April 2015 to June 2015 Ms. Perry also served as Vice President of Finance at Revon Systems, LLC, or Revon, a private health care technology platform company. From August 2000 to April 2015 Ms. Perry worked as an independent consultant providing services to clients primarily in the areas of financial reporting, internal control compliance and as a liaison with external accountants, bankers and legal counsel. Prior to having her consulting practice, Ms. Perry worked in the audit practices of PricewaterhouseCoopers and Deloitte. Ms. Perry is a Certified Public Accountant and received her B.B.A. in accounting, with distinction, from the University of Oklahoma.- Nicole Perry，2015年4月起，担任本公司的财务副总裁。2015年4月至2015年6月，她还担任Revon Systems, LLC的财务副总裁，这是私营的健康护理技术平台公司。2000年8月至2015年4月，她是一名独立顾问，主要为客户提供财务报告 、内部风控合规领域的服务，也是外部会计师、银行家、法律顾问的联络人。拥有自己的顾问公司之前，她在PriceWaterhouseCoopers、Deloitte从事审计工作。她是注册会计师，以优异成绩在University of Oklahoma获得会计方向的工商管理学士学位。
- Nicole Perry has served as our Vice President of Finance since April 2015. From April 2015 to June 2015 Ms. Perry also served as Vice President of Finance at Revon Systems, LLC, or Revon, a private health care technology platform company. From August 2000 to April 2015 Ms. Perry worked as an independent consultant providing services to clients primarily in the areas of financial reporting, internal control compliance and as a liaison with external accountants, bankers and legal counsel. Prior to having her consulting practice, Ms. Perry worked in the audit practices of PricewaterhouseCoopers and Deloitte. Ms. Perry is a Certified Public Accountant and received her B.B.A. in accounting, with distinction, from the University of Oklahoma.
- David Watson
David Watson，2014年1月起，担任本公司的法律总顾问、企业发展副总裁。2014年1月至2015年6月，他还担任Revon的法律总顾问、执行副总裁。2006年至2013年12月，他任职于法律公司Frost Brown Todd LLC，从事股权融资、并购、证券交易。他在Harvard College获得学士学位，在Vanderbilt Law School获得法律博士学位，在University of Kentucky获得数学硕士学位。
David Watson has served as our General Counsel and Vice President of Corporate Development since January 2014. From January 2014 to June 2015 Mr. Watson also served as General Counsel and Executive Vice President of Revon. From 2006 to December 2013 Mr. Watson was a member at the law firm Frost Brown Todd LLC, where his practice included equity finance, mergers and acquisitions and securities transactions. Mr. Watson received his B.A. from Harvard College, his J.D. from Vanderbilt Law School and his M.A. in mathematics from the University of Kentucky.- David Watson，2014年1月起，担任本公司的法律总顾问、企业发展副总裁。2014年1月至2015年6月，他还担任Revon的法律总顾问、执行副总裁。2006年至2013年12月，他任职于法律公司Frost Brown Todd LLC，从事股权融资、并购、证券交易。他在Harvard College获得学士学位，在Vanderbilt Law School获得法律博士学位，在University of Kentucky获得数学硕士学位。
- David Watson has served as our General Counsel and Vice President of Corporate Development since January 2014. From January 2014 to June 2015 Mr. Watson also served as General Counsel and Executive Vice President of Revon. From 2006 to December 2013 Mr. Watson was a member at the law firm Frost Brown Todd LLC, where his practice included equity finance, mergers and acquisitions and securities transactions. Mr. Watson received his B.A. from Harvard College, his J.D. from Vanderbilt Law School and his M.A. in mathematics from the University of Kentucky.
- Steven Axon
Steven Axon自2017年1月起担任我们的首席商务官。从2005年到2016年7月，Axon先生曾在日内瓦和波士顿的Merck Serono担任公司战略，联盟管理和业务发展的领导职务。最近，Axon先生担任高级副总裁，业务开发，负责所有后期阶段和商业交易的全球责任。在此之前，Axon先生是Alliance Management的全球主管，负责40多项战略研究与开发合作。加入Merck Serono之前，Axon从2005年到2007年被Merck KGaA收购，担任日内瓦Serono战略和业务开发主管。在过渡期间，Axon先生担任Merck Serono Integration的Serono业务主管。Axon先生获得了理学学士学位。和M.SC.the University of Toronto的生物力学和生物医学工程学士学位，以及瑞士洛桑International Institute for Management Development的工商管理硕士学位。
Steven Axon has served as our Chief Business Officer since January 2017. From 2005 to July 2016 Mr. Axon served at Merck Serono in Geneva and Boston in leadership roles in Corporate Strategy, Alliance Management and Business Development. Most recently, Mr. Axon served as Senior Vice President, Business Development with global responsibility for all late stage and commercial transactions. Prior to this, Mr. Axon was Global Head of Alliance Management with responsibility for over 40 strategic research and development collaborations. Prior to joining Merck Serono, Mr. Axon was Director of Strategy and Business Development at Serono in Geneva from 2005 until its acquisition by Merck KGaA in 2007. During the transition, Mr. Axon served as the Serono business lead for the Merck Serono integration. Mr. Axon received a B.Sc. and M.Sc. in biomechanical and biomedical engineering from the University of Toronto and his M.B.A. from the International Institute for Management Development in Lausanne, Switzerland.- Steven Axon自2017年1月起担任我们的首席商务官。从2005年到2016年7月，Axon先生曾在日内瓦和波士顿的Merck Serono担任公司战略，联盟管理和业务发展的领导职务。最近，Axon先生担任高级副总裁，业务开发，负责所有后期阶段和商业交易的全球责任。在此之前，Axon先生是Alliance Management的全球主管，负责40多项战略研究与开发合作。加入Merck Serono之前，Axon从2005年到2007年被Merck KGaA收购，担任日内瓦Serono战略和业务开发主管。在过渡期间，Axon先生担任Merck Serono Integration的Serono业务主管。Axon先生获得了理学学士学位。和M.SC.the University of Toronto的生物力学和生物医学工程学士学位，以及瑞士洛桑International Institute for Management Development的工商管理硕士学位。
- Steven Axon has served as our Chief Business Officer since January 2017. From 2005 to July 2016 Mr. Axon served at Merck Serono in Geneva and Boston in leadership roles in Corporate Strategy, Alliance Management and Business Development. Most recently, Mr. Axon served as Senior Vice President, Business Development with global responsibility for all late stage and commercial transactions. Prior to this, Mr. Axon was Global Head of Alliance Management with responsibility for over 40 strategic research and development collaborations. Prior to joining Merck Serono, Mr. Axon was Director of Strategy and Business Development at Serono in Geneva from 2005 until its acquisition by Merck KGaA in 2007. During the transition, Mr. Axon served as the Serono business lead for the Merck Serono integration. Mr. Axon received a B.Sc. and M.Sc. in biomechanical and biomedical engineering from the University of Toronto and his M.B.A. from the International Institute for Management Development in Lausanne, Switzerland.